Bhageria Industries Ltd

The transcript provided on page 27 and surrounding pages does not mention any current or future fundraising plans through debt or equity for Bhageria Industries Limited. Key points regarding financing include: - No explicit mention of any ongoing or planned debt or equity fundraising. - Discussion about CAPEX investments, such as Rs. 152 crore solar project and capacity expansions, funded presumably through internal accruals or existing resources. - Strong balance sheet noted, with stable credit rating (CARE Rating of A1) for Rs. 21 crore facilities indicating good financial health. - Reference to no major Greenfield CAPEX except for some balancing equipment (Rs. 5 crore). - No specific comments on planned loans, equity raises, or fundraising exercises. Therefore, based on the available transcript, there is no indication of Bhageria Industries Limited planning new debt or equity fundraising in the near future.

- Bhageria Industries is undertaking a 100 metric ton CAPEX for H-ACID expansion, with a maximum addition of 500 tons per month at the existing location; further sizable capacity additions will require Greenfield CAPEX. - Planned Greenfield CAPEX for Plasticizer plants is estimated around Rs. 100 crores to add 35,000-36,000 tons annual capacity. - Rs. 10 crore CAPEX has been incurred for the Plasticizer segment by utilizing existing infrastructure. - A 32 MW solar power project is underway, with an investment of Rs. 152 crores; expecting an IRR of approximately 16% and annual revenue of Rs. 22 crores from power purchase agreements. - No new major CAPEX is planned for the pharmaceutical segment; existing CAPEX (~Rs. 30-35 Cr) done for regulatory-compliant GMP plants. - Minor balancing CAPEX (~Rs. 5 crores) planned for existing facilities. - Ethoxylates production line is under study; commercial production expected in next few months.

- Bhageria Industries has experienced strong recent growth, with Q2 FY '26 revenue up 55.6% year-on-year and H1 FY '26 revenue up 48% year-on-year. - Management expects continued revenue growth driven by better volumes rather than price realization. - Export markets, especially for dye intermediates and specialty chemicals, are showing healthy demand and contributing to growth. - Capacity utilization is high at 95%-97%, indicating strong ongoing demand. - The company plans capacity expansions, including a 100 MT CAPEX for H-ACID, which will add about 500 tons/month capacity, with additional expansion requiring Greenfield CAPEX. - The renewable energy segment and expanding specialty chemicals portfolio are expected to contribute meaningfully. - Margins are targeted to improve gradually, helped by reduction in raw material dumping (China stopped dumping recently) and cost efficiencies like solar power installations. - Management remains confident of sustaining growth through product innovation, export diversification, and operational efficiency.

- Management expects margins to improve gradually, targeting around 26-27% in the medium term, though 20% EBITDA margin levels cannot be precisely predicted yet. (Page 25) - Revenue growth driven by volume expansion, especially in chemical segments, is expected to continue with Q3 and Q4 outlook positive, led by export demand and higher utilization (~95-97%) of capacity. (Pages 17, 23) - Specialty Chemicals segment, currently 5-7% of revenue, is projected to grow to approximately 20-22% of revenue, indicating diversification and margin improvement potential. (Page 15) - Plasticizer segment capacity expected to be 2000 tons/month with analyzed margins by Q4 FY26; potential capacity additions likely through Greenfield CAPEX. (Page 8, 16) - Solar business and cost efficiencies (e.g., solar energy for manufacturing) expected to improve margins. (Pages 17, 19) - EBITDAR and net profits have grown significantly (47-83% YoY in recent quarters), reflecting operational leverage and efficient cost management. (Page 5)

The transcript does not explicitly mention the current or expected order book or pending orders for Bhageria Industries Limited. However, relevant information from the call includes: - Demand across key products is described as "good" and "round the clock," indicating steady orders. - Export orders remain strong with no slowdown expected for Q3 and Q4 of FY26. - The company is focusing on export markets, especially Southeast Asia and Europe. - Utilization of installed capacity is high, at about 95%-97%, reflecting full order execution. - The company expects gradual margin improvements and volume growth going forward. - New customers added in China and opportunities in specialty chemicals and pharmaceutical segments suggest pipeline growth. No specific numerical details on order book or pending orders were provided in the transcript.